NCT01046669
Completed
Not Applicable
Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Spectral Diagnostics (US) Inc.0 sites450 target enrollmentJune 2010
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Septic Shock
- Sponsor
- Spectral Diagnostics (US) Inc.
- Enrollment
- 450
- Primary Endpoint
- Mortality
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge, versus subjects who receive standard medical care alone.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Hypotension requiring vasopressor support
- •The subject must have received intravenous fluid resuscitation
- •Documented or suspected infection
- •Endotoxin Activity Assay ≥ 0.60 EAA units
- •Evidence of at least 1 new onset organ dysfunction
Exclusion Criteria
- •Inability to achieve or maintain a minimum mean arterial pressure (MAP) of 65mmHg
- •Subject has end stage renal disease and requires chronic dialysis
- •There is clinical support for non-septic shock
- •Subject has had chest compressions as part of CPR
- •Subject has had an acute myocardial infarction (AMI)
- •Subject has uncontrolled hemorrhage
- •Major trauma within 36 hours of screening
- •Subject has severe granulocytopenia
- •HIV infection with a last known or suspected CD4 count of \<50/mm3
- •Subject has sustained extensive third-degree burns
Outcomes
Primary Outcomes
Mortality
Time Frame: 28 days
Compare mortality at 28 days in subjects treated with standard medical care plus PMX cartridge, versus subjects who received standard medical care alone
Similar Trials
Temporarily Not Available
Not Applicable
Open-label Evaluation of Polymyxin B Hemoperfusion for Septic ShockSeptic ShockEndotoxemiaNCT02825329Spectral Diagnostics (US) Inc.
No Longer Available
Not Applicable
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19Septic ShockEndotoxemiaCOVIDCorona Virus InfectionSepsis, SevereNCT04352985Spectral Diagnostics (US) Inc.
Recruiting
Not Applicable
The effects of polymyxin B hemoperfusion on extra vascular lung water and pulmonary vascular permeabilityJPRN-UMIN000014546Yokohama City University10
Unknown
Not Applicable
Safety and Efficacy of Heparin Dosing Score Protocol for Polymyxin-B HemoperfusionSeptic ShockPolymyxin B HemoperfusionNCT03177330National Taiwan University Hospital30
Terminated
Not Applicable
Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract InfectionSepsisNCT02871024National Taiwan University Hospital1